COMPARISON OF REAL-WORLD TREATMENT PERSISTENCE AND SAFETY OF VEDOLIZUMAB AND ANTI-TUMOR NECROSIS FACTOR-ALPHA TREATMENT IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
Patricia Biedermann 1
Rebecca J. Brown 2
Marlies Neuhold 2
Steve Wisseh 3
Stefan Schreiber 4
1 Takeda Pharmaceuticals International AG, Zurich, Switzerland
2 PHMR Ltd, London, United Kingdom
3 Takeda Pharmaceutical Company Limited, Cambridge, United States
4 Department of Medicine I, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany
Topic
IBD
Session
PP 05 IBD (Posters)
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]